Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm Group has signed a distribution and commercialization agreement with Vifor Pharma for Pamorelin LA and Salvacyl in Switzerland.
Subscribe to our email newsletter
Pamorelin LA is indicated in the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility where as Salvacyl is indicated in the treatment of severe sexual deviation in men.
Vifor Pharma Swiss affiliate general manager Josef Troxler said, "With Debiopharm we have found a renowned Swiss partner. This move will enable us to provide patients and doctors with an innovative product in the areas of oncology and gynaecology."
The one and three-month formulations of Pamorelin LA are available immediately, Vifor Pharma said.
The company will communicate the availability of six-month formulation of Pamorelin LA and Salvacyl at a later date.
The products are manufactured at Debio RP in Martigny, Debiopharm’s site for applied research, controlled release formulation development and production.